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Application of Random Forest and data
integration identifies three dysregulated
genes and enrichment of Central Carbon
Metabolism pathway in Oral Cancer
Srija Mukhopadhyay1, Sahana Ghosh1, Debodipta Das1, P. Arun2, Bidyut Roy3, Nidhan K. Biswas1,
Arindam Maitra1 and Partha P. Majumder1,3*

Abstract
Background: Studies of epigenomic alterations associated with diseases primarily focus on methylation profiles of
promoter regions of genes, but not of other genomic regions. In our past work (Das et al. 2019) on patients
suffering from gingivo-buccal oral cancer – the most prevalent form of cancer among males in India – we have
also focused on promoter methylation changes and resultant impact on transcription profiles. Here, we have
investigated alterations in non-promoter (gene-body) methylation profiles and have carried out an integrative
analysis of gene-body methylation and transcriptomic data of oral cancer patients.
Methods: Tumor and adjacent normal tissue samples were collected from 40 patients. Data on methylation in the
non-promoter (gene-body) regions of genes and transcriptome profiles were generated and analyzed. Because of
high dimensionality and highly correlated nature of these data, we have used Random Forest (RF) and other dataanalytical methods.
Results: Integrative analysis of non-promoter methylation and transcriptome data revealed significant methylationdriven alterations in some genes that also significantly impact on their transcription levels. These changes result in
enrichment of the Central Carbon Metabolism (CCM) pathway, primarily by dysregulation of (a) NTRK3, which plays
a dual role as an oncogene and a tumor suppressor; (b) SLC7A5 (LAT1) which is a transporter dedicated to essential
amino acids, and is overexpressed in cancer cells to meet the increased demand for nutrients that include glucose
and essential amino acids; and, (c) EGFR which has been earlier implicated in progression, recurrence, and stemness
of oral cancer, but we provide evidence of epigenetic impact on overexpression of this gene for the first time.
(Continued on next page)
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Conclusions: In rapidly dividing cancer cells, metabolic reprogramming from normal cells takes place to enable
enhanced proliferation. Here, we have identified that among oral cancer patients, genes in the CCM pathway – that
plays a fundamental role in metabolic reprogramming – are significantly dysregulated because of perturbation of
methylation in non-promoter regions of the genome. This result compliments our previous result that perturbation
of promoter methylation results in significant changes in key genes that regulate the feedback process of DNA
methylation for the maintenance of normal cell division.
Keywords: Random Forest, Epigenomic, Transcriptomic, Integrative analysis, Gingivo-buccal oral cancer

Background
For various cancers both DNA methylation and gene expression data have been analyzed separately and alterations have been found to be associated with
susceptibility and outcome [1, 2]. It is well known that
DNA methylation impacts on gene expression. Therefore, attempts have been made to perform integrative
analyses of these two types of data to draw robust inferences [3]. Various methods of data integration have been
used [4, 5]. Methylation and expression data are high
volume, highly correlated data. Further, the number of
genes or DNA regions/sites on which data are collected
are orders of magnitude higher than the number of patients and controls. This is commonly known as the
“large p, small n” problem or “curse of dimensionality”
in Statistics. Many statistical methods involve inversion
of a matrix for obtaining estimates of parameters. When
the number of variables (p), on which data are available,
for each patient exceeds the total number of patients (n),
inversion of the relevant matrix becomes impossible [6].
This results in parameter estimates that are not unique;
therefore, inferences are liable to be compromised. Random forest (RF) is a machine learning inferential method
that is data-adaptive and tree-based. It handles correlated and large data sets very efficiently and is, therefore
particularly appealing for analysis of high-dimensional
genome data. Normally, only a small portion of a highdimensional data is associated with a phenotype. A regression framework does not apply to this scenario. The
highly correlated nature of genomic data also makes the
application of standard statistical models inappropriate.
RF is a non-parametric tree-based approach that is particularly suited for such data-analysis problems. RF can
also be used to select and rank variables by taking advantage of variable importance measures. A good review
of RF in genomic data analysis can be found [7].
We have used RF methodology to identify gene-body
methylation differences between tumor and adjacent
normal tissues in patients with oral squamous cell carcinoma of the gingivo-buccal region (OSCC-GB), the
most common form of oral cancer in India [8, 9]. We
then integrated the knowledge thus obtained with data
on levels of transcription of genes, which we use as a

proxy for gene-expression levels, to discover
methylation-driven alterations in the gene-body regions
of the genome that significantly associate with dysregulation of genes in oral cancer.
DNA methylation occurs predominantly on cytosines
followed by guanine residues (CpG). This type of methylation is referred to as CpG methylation. Although about
3–4% of all cytosines are methylated in normal human
DNA, there are CpG islands,which are clusters of CpG
dinucleotides in GC-rich regions, that remain unmethylated in all normal tissues [10]. Normally, a gene is transcribed if the CpG island in the promoter region
remains unmethylated. But in cancer, the transcription
of a tumor suppressor gene is silenced by the methylation of promoter CpG island of that gene. We had earlier analyzed data on methylation in CpG sites in the
known promoter regions of all genes, but ignored genebody CpG sites; sites that are on the coding regions of
genes [4]. In our previous study, we identified about 200
genes that showed significant inverse correlation between promoter methylation and expression. These included a set of genes that act as transcription factors
and genes associated with multiple cancer types. A significant finding of the study [4] was the identification of
significant upregulation of CD274 and CD80 via promoter hypomethylation and hence immunosuppressive
effects in OSCC-GB. Since in our previous study we had
not considered gene body methylation, in the present
study we have applied a modern data-adaptive method
(RF) on gene-body methylation data and subsequently
integrated with gene expression data. Our present analysis has resulted in the identification of some dysregulated genes and a pathway that were not identified in
our earlier [4] analysis of promoter methylation and
expression.

Methods
Patient recruitment and sample collection

This study was approved by the Institutional Ethics
Committees of the Tata Medical Centre and the National Institute of Biomedical Genomics, India. Patients
suffering from oral squamous cell carcinoma of the gingivobuccal region (OSCC-GB) were recruited into this
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study with written informed consent. From each patient,
a sample of tumor tissue and adjacent normal tissue
were sampled by one of us (P.A.). The tissue samples
were stored appropriately. TNM staging of 40 tumor
samples were done following the 7th edition of the
American Joint Committee on Cancer (AJCC) [11].
Summary statistics of demographic and clinical characteristics of the patients are provided in Table 1.
DNA methylation

Methylation data from paired tumour and adjacent normal tissue samples of 40 OSCC-GB patients were generated using the Illumina Infinium MethylationEPIC
BeadChip [4]. Using the R package minfi, we estimated
for each CpG site, the CpG-specific methylation level (βvalue) as the ratio of the intensity of methylated (M) to
the combined intensities of both methylated (M) and
unmethylated (U) alleles:

β¼

M
M þ U  þ C

where M* and U* denote signal intensities of M and U
alleles, respectively, and the constant C set at 100 (as
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recommended by the BeadChip manufacturer) [4, 12,
13]. The β-value ranges from 0 (unmethylated) to 1
(methylated). The sites that had a detection p-value
≥0.01 and those that mapped to X or Y chromosomes
were removed. We further removed (a) probes that
masked with “NA” values, (b) SNP associated probes
with minor allele frequency (MAF) > 0.01, (c) probes that
overlapped with a repetitive element, (d) multi-mapped
probes, (e) probes that did not map to annotated
protein-coding genes [4, 12, 14, 15], and (f) probes that
mapped to 3’UTR region of the genome.
Random Forest classifier

To analyze the difference between Tumor and Normal
samples, a Random Forest (RF) method was used on
Methylation data as implemented in the randomForest
package in R [12, 14–19]. The random forest algorithm
is an ensemble classifier similar to Classification and Regression Tree (CART) [17]. Each tree in an RF is built
by choosing a bootstrap sample of two-third of the total
number of individuals; the remaining one-third (Out-OfBag [OOB] sample) is utilised for validation. For each
node in a tree, a binary splitting rule is used on a sample
of CpG sites from the bootstrap sample to find the best
split. The variable with the maximum information gain

Table 1 Demographic and clinical characteristics of 40 gingivo-buccal oral squamous cell carcinoma patients included in this study
Clinical Characteristics*

Frequency

Percent

< 40

7

0.18

40–50

16

0.40

51–60

11

0.28

> 60

6

0.15

Male

33

0.83

Female

7

0.18

Chewing Tobacco

19

0.48

Chewing Tobacco and (Smoking and/or Alcohol)

16

0.40

Age

Gender

Risk-habit

Smoking and/or Alcohol

4

0.10

None

1

0.03

T1

9

0.23

T2

12

0.30

T4

19

0.48

N0

21

0.53

N1

10

0.25

N2

9

0.23

Tumor Stage

Lymph Node Invasion

*All patients were M0 (no metastasis) at the first presentation when tissue samples were collected for analysis
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[20] is selected. A parameter mtry defines the number of
variables randomly selected for each node in a tree, and
another parameter ntree specifies the number of trees to
be built in a forest. Normally, the value of mtry is taken
to be the square root of the number of variables; this is
also the default value in the R package. The output of
randomForest provides an aggregated misclassification
error (OOB error rate), which is estimated from predictions made on the OOB samples, and variable importance, which measures the weighted mean of the
improvement in individual trees by each variable [15–17,
21]. The most reliable variable importance method is
“permutation accuracy importance” or “Mean Decrease
Accuracy” (MDA) [21, 22]. MDA permutes the data of i
th
variable in the OOB sample and records the permuted
OOB error rate. The difference of the original and permuted OOB error rate averaged over the number the
trees gives the importance score for i th variable (VIi) in
the random forest [19, 21–23]. A high value of MDA
implies greater importance of the variable [21, 22].

VI i ¼

tree

1 nX
OOBerror permuted
− OOBerror ij
ij
ntree j¼1

Classification of samples

For efficient computation, only probes with |average
Δβ| ≥ 0.2 were considered, where each Δβ was calculated
by obtaining the difference between the β-values of
tumor and adjacent normal samples of a patient for each
probe indicating differential methylation between them
and then taking average over the number of patients. A
CpG site was considered hypermethylated if average
Δβ ≥ 0.2 and hypomethylated if average Δβ ≤ − 0.2 [4].
Before implementing the random forest (RF) classifier,
ntree and mtry parameters were tuned to generate an
accuracy rate [12, 16]. The best performing combination
of parameters were those for which the OOB error rate
stabilised and reached a minimum; i.e., the combination
of parameters with the highest accuracy rate. Once the
optimum set of parameters was determined, “randomForest” was executed 50 times on the methylation data
of 40 paired samples. In each iteration variables (probes)
with MDA-score > 0 were only selected [18]. The selected probes were then mapped to their respective
genes. A gene was considered for further analyses if it
satisfied the following conditions: (a) there were at least
two probes in the non-promoter region of the gene, (b)
methylation status of all probes in the non-promoter region were unidirectional; either hypermethylated or
hypomethylated, and (c) had no probes in the promoter
region. The stringency of criteria (a) and (b) were
adopted to minimize the chance of false-positive
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discovery, and the criterion (c) was adopted to make discoveries attributable to gene-body methylation only.
RNA sequencing

RNA was extracted and RNA sequencing was performed
to obtain levels of transcription of genes, on the same set
of 40 paired samples. Paired-end libraries were constructed and sequenced using Illumina HiSeq2500 [4, 24].
The quality of the RNA-Seq reads was checked by
FastQC. TopHat2 [4, 24–26] was then used to align these
reads to a hg19 reference transcriptome or genome.
Multi-mapped reads and non-concordant reads were filtered out using SAMtools [4] and duplicate reads were removed using MarkDuplicates from PICARD [4]. Cufflinks
[4, 24–26] was then used to assemble and reconstruct the
transcriptome. Finally, using Cuffnorm, normalised FPKM
values for each gene were estimated [4]. Only those genes
that had non-zero transcription levels in all samples were
considered for further analysis. We have used the level of
transcription of a gene as a proxy for the level of expression of the gene, and have used transcription and expression levels interchangeably in this report.
Integration of methylation and transcription data

Those genes for which there was no promoter probe
and with multiple probes in the non-promoter region
that were uniformly hyper- or hypo-methylated, and for
which the level of transcription/expression change between tumour and normal tissues, averaged over the 40
pairs of samples, was higher than two-fold, were identified to be dysregulated by methylation in non-promoter
regions [4]. Methylation effects on the 1st exon are similar to those of the promoter and exon boundary methylation modulates alternative splicing events [27]. Since
this study is focused on gene expression alterations due
to aberrant methylation on gene body, the genes that
had 1st exon [28, 29] and exon boundary [27, 30] probes
were removed. Finally, we considered only those genes
for mapping on pathways that satisfied the known biological directionality of control; genes with hypermethylation (hypomethylation) in the gene-body region in the
tumour tissue should have a significantly higher (lower)
level of expression in the tumor tissue [31, 32].
Enrichment analysis of pathways

Genes that were so identified by the integration of both
methylation and expression data were analyzed for enrichment of biological pathways. We considered pathways in KEGG for this analysis. ClueGo and CluePedia
plug-ins of Cytoscape were used. To identify whether a
pathway in KEGG was significantly enriched, a rightsided test based on hypergeometric distribution was
used. Benjamini-Hochberg correction method was used
to correct the p-values for multiple testing [4, 33].
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Results
Identification of genes with abundant methylation in the
non-promoter region

A total of 484,420 autosomal probes with detection pvalue < 0.01 were associated with 18,688 genes. After removing 3’UTR and unannotated probes, 333,208 probes
remained which were associated with 18,684 genes. Of
these, 22,711 probes were with |average Δβ| ≥ 0.2 that
mapped to 7027 genes. By fine-tuning (Figure S1), a
stable OOB error rate was obtained with default mtry =
150 and ntree = 2000. Random forest was executed 50
times, with these optimal values of the parameters. The
MDA scores of each variable and OOB error rate were
recorded for 50 iterations. A uniform OOB error rate of
1.25% was observed in each iteration (Table S1). The set
of probes with MDA > 0 comprised 10,105 probes that
mapped to 4831 genes. Among these, for 433 genes
all probes in the non-promoter region were hypermethylated, and for 233 genes all were hypomethylated. We have focused on these 666 unidirectionally
methylated genes, for drawing further inferences integrated with gene expression patterns in tumor-normal
paired tissues.

Integration of methylation and gene-expression

In paired tissues collected from the 40 OSCC-GB patients, non-zero levels of transcription/expression were
found for 477 genes. Considering the 666 genes that exhibited significant and unidirectional methylation, it was
found that 132 of these genes showed at least two-fold
difference in the level of expression between tumour and
normal tissues, averaged over the 40 patients. Of these
132 genes, 8 genes were removed as they had 1st exon
and exon boundary probes. However, of these 124 only
for 67 (54%) genes, the direction of change of expression
level was consistent with that of methylation change
(Table 2). That is, genes with hypermethylation (hypomethylation) in the tumour tissue had significantly
higher (lower) levels of expression in the tumor tissue.

Enriched pathway

The pathway enrichment analysis using the 67 genes
dysregulated by methylation alteration in the gene-body
region between tumour and normal tissues, identified
enrichment of one significant (corrected p-value =
0.0012) KEGG pathway. This was Central Carbon metabolism in Cancer with three associated genes EGFR,
NTRK3, and SLC7A5. It has been reported, based on
cell line studies, that overexpression of EGFR can impact
on the development of solid tumors, including oral cancer [34]. It was found that EGFR was overexpressed and
globally hypermethylated.
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Discussion
By applying the novel Random Forest data-adaptive
method to high-dimensional data (about 500,000 data
points per individual) to identify significant alterations
in gene-body methylation in gingivo-buccal oral tumor
tissue compared to adjacent normal tissue, and subsequent integration with gene expression data it was detected that some genes and pathways were not earlier
inferred to be involved in OSCC-GB only through cellline studies. Although we found that only about 54% of
genes found to have aberrant methylation were also dysregulated in the expected direction, this is not unexpected because gene-body methylation may not be the
only cause of dysregulation of a gene. Hence, the directionality of dysregulation may not be in accord with
what is expected under the methylation-transcription
model. As a matter of fact, it is striking that over 50% of
genes show transcription levels in accord with what is
expected under gene-body hyper- or hypo-methylation.
The significantly enriched pathway that has been identified using this data-adaptive and data-integrative approach is the Central Carbon Metabolism (CCM)
pathway, which is involved in transport and oxidation of
main carbon sources inside the cell. Fundamental cellular processes require energy for growth. The catabolic
and anabolic reactions in metabolism are finely balanced
and tightly regulated. Dysregulation results in cellular
transformation and tumor progression. In rapidly dividing cancer cells, metabolic reprogramming from normal
cells takes place to enable enhanced proliferation. CCM
pathway plays a fundamental role in metabolic reprogramming. Changes in central carbon metabolism of
cancer stem cells have also been noted [35]. It is noteworthy that enrichment of the CCM pathway in OSCCGB takes place by gene-body methylation mediated dysregulation of three key genes, EGFR, NTRK3, SLC7A5
(Fig. 1).
Significant downregulation of NTRK3 mediated by
promoter methylation was noted in our earlier study [4].
NTRK3 is a neurotrophin receptor. It behaves as an
oncogene in breast cancer [36, 37] and possibly also in
hepatocellular carcinoma [38]. However, it also plays a
dual function. It acts as a tumor suppressor in colorectal
cancer in which it is epigenetically inactivated [39]. In
OSCC-GB also, NTRK3 is epigenetically dysregulated
and appears to behave as a tumor suppressor.
SLC7A5 – earlier known as LAT1 – is a transporter
dedicated to essential amino acids. Cancer cells have an
increased demand for nutrients that include glucose and
essential amino acids; the so-called “Warburg effect.”
Overexpression of SLC7A5, as we have observed here, is
explained in part by the presence, in its promoter, of a
canonical binding site for the proto-oncogene c-Myc
[40] that is known to regulate glucose metabolism [41].
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Table 2 Results of 67 genes that showed significant
relationship between methylation in the non-promoter region
and gene expression
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Table 2 Results of 67 genes that showed significant
relationship between methylation in the non-promoter region
and gene expression (Continued)

Gene

Mean of Δβ values of
probes in the nonpromoter region
averaged over all
patients

log2 fold-change of
gene-expression
values averaged
over all patients

Gene

Mean of Δβ values of
probes in the nonpromoter region
averaged over all
patients

log2 fold-change of
gene-expression
values averaged
over all patients

ABCA3

−0.242

−2.740

NCS1

0.290

1.266

ADAMTS17

−0.235

−1.418

NDRG1

0.208

1.343

ADCY2

− 0.282

−4.311

NKAIN1

−0.241

−1.384

ADCYAP1R1

−0.231

−3.227

NTRK3

−0.298

−3.202

AFAP1L2

0.278

1.749

PALM

−0.274

−2.500

AGRN

0.299

1.830

PAPPA

0.258

1.324

ANGPT1

−0.255

−1.084

PARK2

−0.278

−2.854

ANK2

−0.292

−3.425

PDZRN3

−0.250

−1.409

ARNT2

−0.257

−1.056

PLCL1

−0.243

−1.626

ATP8A1

−0.263

−1.419

PML

0.220

1.562

BCL11B

0.344

1.154

PPM1L

−0.303

−2.386

BMPER

−0.226

−2.030

PRKD1

−0.276

−1.051

BNC2

−0.284

− 2.276

RGS20

0.221

2.582

CACNA1D

−0.261

−2.461

RTKN

0.235

1.183

CACNA2D1

−0.256

−2.616

SCIN

−0.278

−3.784

CADM1

−0.256

−1.519

SDK2

0.247

2.410

CDCA7

0.235

1.265

SLC6A17

−0.240

−1.586

CIT

0.274

1.201

SLC7A5

0.241

1.367

CLIC5

−0.264

−3.547

SOBP

−0.286

−2.687

COBL

−0.283

−3.073

SPRED3

0.280

1.989

COL27A1

0.323

1.918

SUSD4

−0.319

−1.780

DNAH17

0.228

3.230

TECTA

−0.286

−1.007

EEPD1

−0.245

−1.291

TENM2

0.275

2.951

EGFR

0.240

1.147

TMEM232

−0.213

−1.995

EPHB2

0.285

2.239

TRAM2

0.264

1.327

EPSTI1

0.269

2.851

WNK2

−0.217

−3.895

EXT1

0.272

1.068

ZNF423

−0.254

−1.799

FAM13C

−0.340

−1.862

FAM171A1

−0.232

−1.712

FGD5

−0.266

−1.149

FHIT

−0.289

−2.022

GFI1

0.318

1.787

ICAM5

0.301

1.476

IGDCC4

−0.296

−2.178

KCNAB1

−0.279

−1.560

LAMB4

−0.206

− 1.731

LDB2

−0.268

−1.250

LRP8

0.227

1.393

MCF2L

−0.242

−2.238

MEGF11

−0.257

−1.094

Overexpression of SLC7A5 is also controlled by methylation in the promoter [4] and non-promoter regions
(this study).
EGFR has been earlier implicated in progression, recurrence, and stemness of oral cancer [42, 43]. EGFR is
inappropriately activated in cancer mainly because of
amplification and point mutations. Transcriptional upregulation of EGFR due to autocrine/paracrine mechanisms has also been described [44]. Here, for the first
time, it is shown that dysregulation of EGFR takes place
by epigenetic mechanisms in oral cancer.
Cancer cells rapidly multiply. Significant metabolic
changes occur during cancer development and progression. Cancer cells have a lot of metabolic requirement
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Fig. 1 Genes found altered in Central Carbon Metabolism (CCM) pathway in gingivo-buccal oral cancer. EGFR, SLC7A5, NTRK3, the three key
genes (marked in blue and appearing on the vertical lines to the left of the figure), were significantly dysregulated in the CCM pathway

for the increase of their biomass and genome. These include the increased demand for nutrients such as glucose, essential amino acids and also glutamine, that
becomes conditionally essential, for protein synthesis
and/or energy supply [45–48]. Cancer cells utilize large
amounts of glucose and glutamine and maintain high
rates of glycolysis and glutaminolysis; called the Warburg effect. These increased requirements are met by
the cancer cells themselves. Cancer cells undergo a large
number of mutations, some of which take place in genes
that belong to specific pathways, such as the central carbon metabolism pathway, which help meet these additional requirements. The central carbon metabolism
pathway is large, complex and performs a variety of
functions. About 70 genes are involved in this pathway,
that are involved in a variety of functions that include
glucose import, glycolysis, pentose phosphate flux, lactate excretion, pyruvate dehydrogenase flux, TCA cycle
flux, pyruvate carboxylase flux, gluconeogenic flux, glycine biosynthesis, glutathione biosynthesis, proline biosynthesis, palmitate biosynthesis (fatty acid synthase
activity), desaturation of palmitate, elongation of palmitate, and desaturation of stearate [49]. Changes in one or
more components of the central carbon metabolism

pathway have been identified in various cancers. The
genes that we have found to be significantly altered
in their levels of expression resulting from genebody methylation changes – NTRK3, SLC7A5
(LAT1) and EGFR – belong to the subcomponents
related to the Warburg effect, notably glucose import and glycolysis.

Conclusions
Three key genes NTRK3, SLC7A5 (LAT1) and EGFR
were dysregulated in the CCM pathway. Of these,
NTRK3 [4, 50] and SLC7A5 [4] were earlier identified to
be associated with oral cancer. However, we provide the
first evidence of epigenetic impact on overexpression of
EGFR in oral cancer. To enable enhanced proliferation
of cells in a cancer tissue, metabolic reprogramming
from normal cells usually takes place. In the present
analysis, we have identified that among oral cancer patients, genes in the CCM pathway – that plays a fundamental role in metabolic reprogramming – are
significantly dysregulated because of perturbation of
methylation in non-promoter regions of the genome.
This result compliments our previous result that perturbation of promoter methylation results in significant
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changes in key genes that regulate the feedback process
of DNA methylation for the maintenance of normal cell
division. Taken together, it is evident that in oral cancer
methylation driven alterations in both promoter and
non-promoter genomic regions result in disruption of
normal cell division accompanied by metabolic reprogramming to enable rapid cell proliferation.
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